No profile data available.
Indivior PLC (INDV) is a healthcare company in the poison treatment pharmaceuticals industry, based in North Chesterfield, United States, with about 827 full-time employees.
It reported revenue of $1.24 billion for fiscal year 2025, up 4.3% from fiscal year 2024, and net income of $210.00 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $343.00 million, up 13.6% from a year before. Its market capitalization was $4.23 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders.
Indivior reported $1.24 billion in revenue for fiscal year 2025, up 4.3% from $1.19 billion in fiscal year 2024. In Q2 2026 revenue was $343.00 million.
$4.23 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (poison treatment pharmaceuticals) include Achieve Life Sciences, Inc. (ACHV), Aquestive Therapeutics, Inc. (AQST), Fennec Pharmaceuticals Inc. (FENC), Anebulo Pharmaceuticals, Inc. (ANEB).